Literature DB >> 30298470

Diagnosis of nontuberculous mycobacterial disease in the era of surveillance chest CT scans.

Andrew Calzadilla1, Greg Holt1,2, Michael Campos1,2, Mehdi Mirsaeidi3,4,5.   

Abstract

The radiologic surveillance of smokers with low-dose CT scan has led to a significant surge of radiologic incidental findings, including the detection of early stages of pulmonary infections including nontuberculous mycobacteria (NTM). This causes a state of overdiagnosis and potential overtreatment of NTM lung disease. Here we propose a new approach to NTM pulmonary disease in the era of increased CT scanning.

Entities:  

Keywords:  Lung disease; MAC; Mycobacterial; Nontuberculous

Mesh：

Year:  2018        PMID： 30298470     DOI： 10.1007/s15010-018-1232-3

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  9 in total

1.  Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease.

Authors:  Kevin L Winthrop; Erin McNelley; Brian Kendall; Allison Marshall-Olson; Christy Morris; Maureen Cassidy; Ashlen Saulson; Katrina Hedberg
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 2.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

Review 3.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

4.  Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF).

Authors:  Laura Viviani; Michael J Harrison; Anna Zolin; Charles S Haworth; R Andres Floto
Journal:  J Cyst Fibros       Date:  2016-04-01       Impact factor: 5.482

5.  Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease.

Authors:  Theodore K Marras; Michael A Campitelli; Jeffrey C Kwong; Hong Lu; Sarah K Brode; Alex Marchand-Austin; Andrea S Gershon; Frances B Jamieson
Journal:  Eur Respir J       Date:  2016-06-10       Impact factor: 16.671

Review 6.  Nonresolving or slowly resolving pneumonia.

Authors:  T Kuru; J P Lynch
Journal:  Clin Chest Med       Date:  1999-09       Impact factor: 2.878

7.  Results of initial low-dose computed tomographic screening for lung cancer.

Authors:  Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum
Journal:  N Engl J Med       Date:  2013-05-23       Impact factor: 91.245

Review 8.  Nontuberculous mycobacterial pulmonary infections.

Authors:  Margaret M Johnson; John A Odell
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

9.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.